Nanodrug against vitiligo
Successful in-vitro test shows potential for new treatment
Vitiligo is a disease characterized by loss of skin pigmentation due to the death of cells called melanocytes, responsible for melanin production. This disease afflicts up to 1% of the world population and current treatments are not effective and exhibit several side effects.
According to the most accepted theory, the disease results from an autoimmune reaction. It is known that one of the proteins involved in melanin synthesis, called TyRP-1, also functions as a melanocyte differentiation antigen, marking the melanocytes to be attacked by the immune system. Therefore, a possible strategy to thwart the progression of the disease is to prevent the production of TyRP-1.